Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04739813
Title Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

B-cell lymphoma

Burkitt lymphoma

diffuse large B-cell lymphoma

Therapies

Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center Recruiting Bethesda Maryland 20892 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field